Register to Describe the Treatment Pattern of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Patients in Austria
NCT ID: NCT04369352
Last Updated: 2023-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
150 participants
OBSERVATIONAL
2018-08-09
2025-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The register will provide an overview of chosen treatments including the reasons, why these options were chosen.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Validation of a Score of Predictive Factors for Complete Resection in Platinum-sensitive Recurrent Ovarian Cancer
NCT00368420
Platino-resistance in Ovarian Cancer
NCT03954171
Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian Cancer
NCT04830709
HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma
NCT02487849
Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers
NCT04795596
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
These are all patients with recurrent disease 6 or more months after the last cycle of platinum containing chemotherapy.
The Observation Period will begin by signing the Informed Consent Form (ICF) and will continue for up to a total of 24 months (+/- 4 weeks) after the diagnosis of the first relapse or until patient discontinuation for any reason, or patient's death.
Data on First Study Visit, Subsequent Recurrence during Observation Period and Last Observation will be collected in the electronic Case Report Form (eCRF).
The register will identify symptoms and factors that led to the diagnosis, chosen therapy and the reason for choosing the therapy. At inclusion, data on general patient information, primary diagnosis, previous therapy, and tumor characteristics are collected. During the course of observation data on systemic and maintenance treatments, radiotherapies, surgeries, and outcome are documented.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presence of first platinum-sensitive ROC (ovarian, peritoneal and/or fallopian tube cancer)
* Must have received at least 4 cycles of chemotherapy during primary therapy
* At time of inclusion a treatment for ROC must be planned
* Patients must not have more than 1 prior line of chemotherapy
* Signed informed consent
Exclusion Criteria
* Signed informed consent is not given
18 Years
99 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University Innsbruck
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lukas Hefler, Prim. Dr.
Role: PRINCIPAL_INVESTIGATOR
Ordensklinikum Linz
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kepler Universitätsklinikum Linz
Linz, , Austria
Ordensklinikum Linz
Linz, , Austria
Medical University Graz
Graz, , Austria
Medical University Innsbruck
Innsbruck, , Austria
Bezirkskrankenhaus Kufstein
Kufstein, , Austria
LKH Hochsteiermark
Leoben, , Austria
Bezirkskrankenhaus Lienz
Lienz, , Austria
Krankenhaus der Barmherzigen Schwestern Ried
Ried im Innkreis, , Austria
Medical University Vienna
Vienna, , Austria
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Edgar Petru, Prof. Dr.
Role: primary
Christian Marth, Prof. Dr.
Role: primary
Rainer Heider, Prim. Dr.
Role: primary
Florentia Peintinger, Prof. PD Dr.
Role: primary
Birgit Volgger, Prim. Dr.
Role: primary
Lukas Angleitner-Boubenizek, OA Dr.
Role: primary
Lukas Hefler, Prim. Dr.
Role: primary
Florian Baminger, OA Dr.
Role: primary
Alexander Reinthaller, Prof. Dr.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AGO R03 ROC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.